Acadesine API Manufacturers
compare suppliers & get competitive offers
Filters
Reset
Selected filters:
Type
Production region
Qualifications
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Acadesine API 2627-69-2?
- Description:
- Here you will find a list of producers, manufacturers and traders of Acadesine. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Acadesine
- Synonyms:
- AICA-riboside
- Cas Number:
- 2627-69-2
- DrugBank number:
- DB04944
- Unique Ingredient Identifier:
- 53IEF47846
About Acadesine
Want to know what Acadesine is used for? Acadesine (AICA-riboside) is a purine nucleoside analog with anti-ischemic properties that is currently being studied (Phase 3) for the prevention of adverse cardiovascular outcomes in patients undergoing coronary artery bypass graft (CABG) surgery. It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.
Check who is selling Acadesine in the overview above.
Acadesine is a type of Glycemic Agents
Glycemic agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are widely used in the treatment of diabetes mellitus. These agents play a crucial role in managing blood glucose levels and improving glycemic control in individuals with diabetes.
One of the key classes of glycemic agents is oral hypoglycemic agents, which are taken by mouth and help lower blood sugar levels. This class includes various subclasses such as sulfonylureas, biguanides, meglitinides, and alpha-glucosidase inhibitors. Sulfonylureas stimulate the release of insulin from the pancreas, while biguanides decrease the production of glucose in the liver and improve insulin sensitivity. Meglitinides work by stimulating insulin secretion, and alpha-glucosidase inhibitors slow down the absorption of carbohydrates from the intestine.
Another important class of glycemic agents is injectable insulin. Insulin is a hormone that regulates glucose metabolism in the body. It is administered via subcutaneous injections and comes in different forms, including short-acting, intermediate-acting, and long-acting insulin. These different formulations allow for precise control of blood glucose levels throughout the day.
Glycemic agents are prescribed based on various factors such as the type of diabetes, severity of the condition, and individual patient characteristics. They are typically used in combination with dietary modifications and lifestyle changes to achieve optimal glycemic control.
Overall, glycemic agents are vital components in the management of diabetes, helping individuals maintain stable blood sugar levels and reducing the risk of complications associated with uncontrolled diabetes.
